Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group

T. M. Westers, R. Ireland, W. Kern, C. Alhan, J. S. Balleisen, P. Bettelheim, K. Burbury, M. Cullen, J. A. Cutler, M. G. Della Porta, A. M. Dräger, J. Feuillard, P. Font, U. Germing, D. Haase, U. Johansson, S. Kordasti, M. R. Loken, L. Malcovati, J. G. Te MarveldeS. Matarraz, T. Milne, B. Moshaver, G. J. Mufti, K. Ogata, A. Orfao, A. Porwit, K. Psarra, S. J. Richards, D. Subirá, V. Tindell, T. Vallespi, P. Valent, V. H J Van Der Velden, T. M. De Witte, D. A. Wells, F. Zettl, M. C. Béné, A. A. Van De Loosdrecht

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as normal, suggestive of, or diagnostic of MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.

Original languageEnglish
Pages (from-to)1730-1741
Number of pages12
JournalLeukemia
Volume26
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Myelodysplastic Syndromes
Flow Cytometry
Education

Keywords

  • consensus
  • ELN
  • flow cytometry
  • myelodysplastic syndromes
  • standardization

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Westers, T. M., Ireland, R., Kern, W., Alhan, C., Balleisen, J. S., Bettelheim, P., ... Van De Loosdrecht, A. A. (2012). Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group. Leukemia, 26(7), 1730-1741. https://doi.org/10.1038/leu.2012.30

Standardization of flow cytometry in myelodysplastic syndromes : A report from an international consortium and the European LeukemiaNet Working Group. / Westers, T. M.; Ireland, R.; Kern, W.; Alhan, C.; Balleisen, J. S.; Bettelheim, P.; Burbury, K.; Cullen, M.; Cutler, J. A.; Della Porta, M. G.; Dräger, A. M.; Feuillard, J.; Font, P.; Germing, U.; Haase, D.; Johansson, U.; Kordasti, S.; Loken, M. R.; Malcovati, L.; Te Marvelde, J. G.; Matarraz, S.; Milne, T.; Moshaver, B.; Mufti, G. J.; Ogata, K.; Orfao, A.; Porwit, A.; Psarra, K.; Richards, S. J.; Subirá, D.; Tindell, V.; Vallespi, T.; Valent, P.; Van Der Velden, V. H J; De Witte, T. M.; Wells, D. A.; Zettl, F.; Béné, M. C.; Van De Loosdrecht, A. A.

In: Leukemia, Vol. 26, No. 7, 07.2012, p. 1730-1741.

Research output: Contribution to journalArticle

Westers, TM, Ireland, R, Kern, W, Alhan, C, Balleisen, JS, Bettelheim, P, Burbury, K, Cullen, M, Cutler, JA, Della Porta, MG, Dräger, AM, Feuillard, J, Font, P, Germing, U, Haase, D, Johansson, U, Kordasti, S, Loken, MR, Malcovati, L, Te Marvelde, JG, Matarraz, S, Milne, T, Moshaver, B, Mufti, GJ, Ogata, K, Orfao, A, Porwit, A, Psarra, K, Richards, SJ, Subirá, D, Tindell, V, Vallespi, T, Valent, P, Van Der Velden, VHJ, De Witte, TM, Wells, DA, Zettl, F, Béné, MC & Van De Loosdrecht, AA 2012, 'Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group', Leukemia, vol. 26, no. 7, pp. 1730-1741. https://doi.org/10.1038/leu.2012.30
Westers, T. M. ; Ireland, R. ; Kern, W. ; Alhan, C. ; Balleisen, J. S. ; Bettelheim, P. ; Burbury, K. ; Cullen, M. ; Cutler, J. A. ; Della Porta, M. G. ; Dräger, A. M. ; Feuillard, J. ; Font, P. ; Germing, U. ; Haase, D. ; Johansson, U. ; Kordasti, S. ; Loken, M. R. ; Malcovati, L. ; Te Marvelde, J. G. ; Matarraz, S. ; Milne, T. ; Moshaver, B. ; Mufti, G. J. ; Ogata, K. ; Orfao, A. ; Porwit, A. ; Psarra, K. ; Richards, S. J. ; Subirá, D. ; Tindell, V. ; Vallespi, T. ; Valent, P. ; Van Der Velden, V. H J ; De Witte, T. M. ; Wells, D. A. ; Zettl, F. ; Béné, M. C. ; Van De Loosdrecht, A. A. / Standardization of flow cytometry in myelodysplastic syndromes : A report from an international consortium and the European LeukemiaNet Working Group. In: Leukemia. 2012 ; Vol. 26, No. 7. pp. 1730-1741.
@article{79850f2ef93b4ef4b277266fc26c24c9,
title = "Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group",
abstract = "Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as normal, suggestive of, or diagnostic of MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.",
keywords = "consensus, ELN, flow cytometry, myelodysplastic syndromes, standardization",
author = "Westers, {T. M.} and R. Ireland and W. Kern and C. Alhan and Balleisen, {J. S.} and P. Bettelheim and K. Burbury and M. Cullen and Cutler, {J. A.} and {Della Porta}, {M. G.} and Dr{\"a}ger, {A. M.} and J. Feuillard and P. Font and U. Germing and D. Haase and U. Johansson and S. Kordasti and Loken, {M. R.} and L. Malcovati and {Te Marvelde}, {J. G.} and S. Matarraz and T. Milne and B. Moshaver and Mufti, {G. J.} and K. Ogata and A. Orfao and A. Porwit and K. Psarra and Richards, {S. J.} and D. Subir{\'a} and V. Tindell and T. Vallespi and P. Valent and {Van Der Velden}, {V. H J} and {De Witte}, {T. M.} and Wells, {D. A.} and F. Zettl and B{\'e}n{\'e}, {M. C.} and {Van De Loosdrecht}, {A. A.}",
year = "2012",
month = "7",
doi = "10.1038/leu.2012.30",
language = "English",
volume = "26",
pages = "1730--1741",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Standardization of flow cytometry in myelodysplastic syndromes

T2 - A report from an international consortium and the European LeukemiaNet Working Group

AU - Westers, T. M.

AU - Ireland, R.

AU - Kern, W.

AU - Alhan, C.

AU - Balleisen, J. S.

AU - Bettelheim, P.

AU - Burbury, K.

AU - Cullen, M.

AU - Cutler, J. A.

AU - Della Porta, M. G.

AU - Dräger, A. M.

AU - Feuillard, J.

AU - Font, P.

AU - Germing, U.

AU - Haase, D.

AU - Johansson, U.

AU - Kordasti, S.

AU - Loken, M. R.

AU - Malcovati, L.

AU - Te Marvelde, J. G.

AU - Matarraz, S.

AU - Milne, T.

AU - Moshaver, B.

AU - Mufti, G. J.

AU - Ogata, K.

AU - Orfao, A.

AU - Porwit, A.

AU - Psarra, K.

AU - Richards, S. J.

AU - Subirá, D.

AU - Tindell, V.

AU - Vallespi, T.

AU - Valent, P.

AU - Van Der Velden, V. H J

AU - De Witte, T. M.

AU - Wells, D. A.

AU - Zettl, F.

AU - Béné, M. C.

AU - Van De Loosdrecht, A. A.

PY - 2012/7

Y1 - 2012/7

N2 - Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as normal, suggestive of, or diagnostic of MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.

AB - Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as normal, suggestive of, or diagnostic of MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.

KW - consensus

KW - ELN

KW - flow cytometry

KW - myelodysplastic syndromes

KW - standardization

UR - http://www.scopus.com/inward/record.url?scp=84863785114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863785114&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.30

DO - 10.1038/leu.2012.30

M3 - Article

C2 - 22307178

AN - SCOPUS:84863785114

VL - 26

SP - 1730

EP - 1741

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -